K-One MM

K-One MM

Injection

🧬 Phytomenadione 🏢 Square Pharmaceuticals PLC
Generic Name Phytomenadione
Manufacturer Square Pharmaceuticals PLC
Unit Price 2 mg ampoule: ৳ 19.94 (2 x 3: ৳ 119.64)

🔹 Indications

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Pharmacology

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Dosage & Administration

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Interaction

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Contraindications

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Side Effects

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Precautions & Warnings

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Storage Conditions

K-One MM (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

💡 Frequently Asked Questions

K-One MM (Vitamin K-1) is indicated in following indications- Prophylaxis and treatment of haemorrhagic disease in the newborn. Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII...
K-One MM (Vitamin K-1) is indicated in following indications- Prophylaxis and treatment of haemorrhagic disease in the newborn. Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII...
K-One MM (Vitamin K-1) is indicated in following indications- Prophylaxis and treatment of haemorrhagic disease in the newborn. Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII...

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review